Brain metastases and testicular tumors: Long-term survival

Wayne T. Spears, James G. Morphis, Steven G. Lester, Stephen D. Williams, Lawrence Einhorn

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

In this updated and expanded retrospective analysis, the treatment records of 24 patients with brain metastases from nonseminomatous germ cell testicular tumors (NSGCT's) treated at the Indiana University Department of Radiation Oncology from 1975 through 1988 were reviewed. All patients received standard cisplatin-based induction chemotherapy. These patients were divided into three groups. Group 1 (n = 10) consisted of patients who presented initially with brain metastases and had no prior systemic treatment. Group 2 (n = 4) consisted of those patients who, after achieving a complete response (CR) with cisplatin, vinblastine, and bleomycin (PVB) ± doxorubicin, developed a relapse confined to the brain. Group 3 (n = 10) consisted of those patients who were initially treated with PVB ± doxorubicin or bleomycin, etoposide, and cisplatin (BEP) and eventually developed progressive disease and brain metastases. Group 1 was treated with whole brain irradiation (WBRT) and PVB ± doxorubicin or BEP. Group 2 was treated with WBRT, cisplatin-based chemotherapy ± surgical excision. Group 3 was usually treated with WBRT palliatively. Six patients, three in Group 1 and three in Group 2, are alive and disease-free with follow-up of 5+ years from beginning WBRT. Two additional patients in Group 1 survived 5+ years from beginning WBRT before dying with disease. No patient in Group 3 survived. Patients with brain metastases who have potentially controllable systemic disease should be treated curatively with WBRT ( 5000 cGy 25 fractions) ± surgical excision and concomitant chemotherapy.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume22
Issue number1
DOIs
StatePublished - 1992

Fingerprint

Testicular Neoplasms
metastasis
Brain Neoplasms
brain
tumors
Neoplasm Metastasis
Survival
Brain
Cisplatin
Bleomycin
irradiation
chemotherapy
Doxorubicin
Etoposide
Drug Therapy
Radiation Oncology
Induction Chemotherapy
Vinblastine
Brain Diseases
induction

Keywords

  • Brain metastasis
  • Testicular neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Brain metastases and testicular tumors : Long-term survival. / Spears, Wayne T.; Morphis, James G.; Lester, Steven G.; Williams, Stephen D.; Einhorn, Lawrence.

In: International Journal of Radiation Oncology Biology Physics, Vol. 22, No. 1, 1992, p. 17-22.

Research output: Contribution to journalArticle

Spears, Wayne T. ; Morphis, James G. ; Lester, Steven G. ; Williams, Stephen D. ; Einhorn, Lawrence. / Brain metastases and testicular tumors : Long-term survival. In: International Journal of Radiation Oncology Biology Physics. 1992 ; Vol. 22, No. 1. pp. 17-22.
@article{a494628ee93c456e90afc87a18527f35,
title = "Brain metastases and testicular tumors: Long-term survival",
abstract = "In this updated and expanded retrospective analysis, the treatment records of 24 patients with brain metastases from nonseminomatous germ cell testicular tumors (NSGCT's) treated at the Indiana University Department of Radiation Oncology from 1975 through 1988 were reviewed. All patients received standard cisplatin-based induction chemotherapy. These patients were divided into three groups. Group 1 (n = 10) consisted of patients who presented initially with brain metastases and had no prior systemic treatment. Group 2 (n = 4) consisted of those patients who, after achieving a complete response (CR) with cisplatin, vinblastine, and bleomycin (PVB) ± doxorubicin, developed a relapse confined to the brain. Group 3 (n = 10) consisted of those patients who were initially treated with PVB ± doxorubicin or bleomycin, etoposide, and cisplatin (BEP) and eventually developed progressive disease and brain metastases. Group 1 was treated with whole brain irradiation (WBRT) and PVB ± doxorubicin or BEP. Group 2 was treated with WBRT, cisplatin-based chemotherapy ± surgical excision. Group 3 was usually treated with WBRT palliatively. Six patients, three in Group 1 and three in Group 2, are alive and disease-free with follow-up of 5+ years from beginning WBRT. Two additional patients in Group 1 survived 5+ years from beginning WBRT before dying with disease. No patient in Group 3 survived. Patients with brain metastases who have potentially controllable systemic disease should be treated curatively with WBRT ( 5000 cGy 25 fractions) ± surgical excision and concomitant chemotherapy.",
keywords = "Brain metastasis, Testicular neoplasms",
author = "Spears, {Wayne T.} and Morphis, {James G.} and Lester, {Steven G.} and Williams, {Stephen D.} and Lawrence Einhorn",
year = "1992",
doi = "10.1016/0360-3016(92)90977-P",
language = "English",
volume = "22",
pages = "17--22",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Brain metastases and testicular tumors

T2 - Long-term survival

AU - Spears, Wayne T.

AU - Morphis, James G.

AU - Lester, Steven G.

AU - Williams, Stephen D.

AU - Einhorn, Lawrence

PY - 1992

Y1 - 1992

N2 - In this updated and expanded retrospective analysis, the treatment records of 24 patients with brain metastases from nonseminomatous germ cell testicular tumors (NSGCT's) treated at the Indiana University Department of Radiation Oncology from 1975 through 1988 were reviewed. All patients received standard cisplatin-based induction chemotherapy. These patients were divided into three groups. Group 1 (n = 10) consisted of patients who presented initially with brain metastases and had no prior systemic treatment. Group 2 (n = 4) consisted of those patients who, after achieving a complete response (CR) with cisplatin, vinblastine, and bleomycin (PVB) ± doxorubicin, developed a relapse confined to the brain. Group 3 (n = 10) consisted of those patients who were initially treated with PVB ± doxorubicin or bleomycin, etoposide, and cisplatin (BEP) and eventually developed progressive disease and brain metastases. Group 1 was treated with whole brain irradiation (WBRT) and PVB ± doxorubicin or BEP. Group 2 was treated with WBRT, cisplatin-based chemotherapy ± surgical excision. Group 3 was usually treated with WBRT palliatively. Six patients, three in Group 1 and three in Group 2, are alive and disease-free with follow-up of 5+ years from beginning WBRT. Two additional patients in Group 1 survived 5+ years from beginning WBRT before dying with disease. No patient in Group 3 survived. Patients with brain metastases who have potentially controllable systemic disease should be treated curatively with WBRT ( 5000 cGy 25 fractions) ± surgical excision and concomitant chemotherapy.

AB - In this updated and expanded retrospective analysis, the treatment records of 24 patients with brain metastases from nonseminomatous germ cell testicular tumors (NSGCT's) treated at the Indiana University Department of Radiation Oncology from 1975 through 1988 were reviewed. All patients received standard cisplatin-based induction chemotherapy. These patients were divided into three groups. Group 1 (n = 10) consisted of patients who presented initially with brain metastases and had no prior systemic treatment. Group 2 (n = 4) consisted of those patients who, after achieving a complete response (CR) with cisplatin, vinblastine, and bleomycin (PVB) ± doxorubicin, developed a relapse confined to the brain. Group 3 (n = 10) consisted of those patients who were initially treated with PVB ± doxorubicin or bleomycin, etoposide, and cisplatin (BEP) and eventually developed progressive disease and brain metastases. Group 1 was treated with whole brain irradiation (WBRT) and PVB ± doxorubicin or BEP. Group 2 was treated with WBRT, cisplatin-based chemotherapy ± surgical excision. Group 3 was usually treated with WBRT palliatively. Six patients, three in Group 1 and three in Group 2, are alive and disease-free with follow-up of 5+ years from beginning WBRT. Two additional patients in Group 1 survived 5+ years from beginning WBRT before dying with disease. No patient in Group 3 survived. Patients with brain metastases who have potentially controllable systemic disease should be treated curatively with WBRT ( 5000 cGy 25 fractions) ± surgical excision and concomitant chemotherapy.

KW - Brain metastasis

KW - Testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0026502358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026502358&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(92)90977-P

DO - 10.1016/0360-3016(92)90977-P

M3 - Article

C2 - 1370066

AN - SCOPUS:0026502358

VL - 22

SP - 17

EP - 22

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -